Publication | Closed Access

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

Gastrointestinal OncologyMedicinePathologyFirst-line TreatmentPharmacotherapyCancer TreatmentPhase 2OncologyRadiation OncologyCancer ResearchOesophagogastric Junction Adenocarcinoma